Media coverage about Enanta Pharmaceuticals (NASDAQ:ENTA) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.1272066421177 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Enanta Pharmaceuticals (NASDAQ:ENTA) opened at $47.68 on Thursday. The firm has a market cap of $871.48, a price-to-earnings ratio of 51.88 and a beta of 0.66. Enanta Pharmaceuticals has a 1-year low of $25.92 and a 1-year high of $50.92.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share for the quarter, missing the consensus estimate of $2.13 by ($0.27). The firm had revenue of $75.93 million during the quarter, compared to the consensus estimate of $73.80 million. Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The company’s quarterly revenue was up 491.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.09) EPS. equities analysts predict that Enanta Pharmaceuticals will post -0.95 earnings per share for the current year.

A number of equities research analysts have recently issued reports on ENTA shares. JMP Securities boosted their price objective on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 11th. Royal Bank Of Canada reissued a “buy” rating and set a $54.00 price objective on shares of Enanta Pharmaceuticals in a research report on Friday, October 20th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, Robert W. Baird boosted their price objective on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $46.25.

COPYRIGHT VIOLATION WARNING: “Enanta Pharmaceuticals (ENTA) Receives News Impact Score of 0.08” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/enanta-pharmaceuticals-enta-receives-news-impact-score-of-0-08/1720786.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.